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Abstract. This prospective cohort study describes travelers’ diarrhea (TD) and non-TD gastrointestinal (GI) symp-
toms among international travelers from the Boston area, the association of TD with traveler characteristics and
dietary practices, use of prescribed antidiarrheal medications, and the impact of TD and non-TD GI symptoms on
planned activities during and after travel. We included adults who received a pre-travel consultation at three Boston-
area travel clinics and who completed a three-part survey: pre-travel, during travel, and post-travel (2–4 weeks after
return). TD was defined as self-reported diarrhea with or without nausea/vomiting, abdominal pain, or fever. Demo-
graphic and travel characteristics were evaluated by χ2 test for categorical and Wilcoxon rank-sum test for con-
tinuous variables. Analysis of dietary practices used logistic generalized estimating equation models or logistic
regression models. Of 628 travelers, 208 (33%) experienced TD and 45 (7%) experienced non-TD GI symptoms.
Of 208 with TD, 128 (64%), 71 (36%), and 123 (62%) were prescribed ciprofloxacin, azithromycin, and/or loperamide
before travel, respectively. Thirty-nine (36%) of 108 took ciprofloxacin, 20 (38%) of 55 took azithromycin, and
28 (28%) of 99 took loperamide during travel. Of 172 with TD during travel, 24% stopped planned activities, and 2%
were hospitalized. Of 31 with non-TD GI symptoms during travel, six (13%) stopped planned activities. International
travelers continue to experience diarrhea and other GI symptoms, resulting in disruption of planned activities and
healthcare visits for some. Although these illnesses resulted in interruption of travel plans, a relatively small proportion
took prescribed antibiotics.
INTRODUCTION
Travelers’ diarrhea (TD) and non-TD gastrointestinal (GI)
symptoms are common among international travelers. In a
study of short-term travelers from Switzerland to develop-
ing countries, the most common symptom experienced
was severe diarrhea (8.5%) followed by vomiting or abdom-
inal cramps (4%).1 GI illnesses were the most frequently
reported diagnoses (34%) among ill-returned travelers to
GeoSentinel clinics.2 Of those returning to U.S. GeoSentinel
clinics, acute diarrhea (30%) was the most common diag-
nosis.3 In one cohort of U.S. travelers, 46% reported diar-
rhea.4 GI illnesses can last from 2 days to weeks or longer,5
disrupting plans during travel or after returning home.
Eighty percent of those who experienced diarrhea during
travel treated themselves with medication and 6% sought
medical care.4
Pre-travel medical advice typically includes destination-
specific food and water precautions (such as eating only
food that is cooked and served hot and drinking only bot-
tled water), counseling about management of diarrhea, and
prescriptions for medications to self-treat diarrhea. Adher-
ing to food and water precautions can be difficult while
traveling and does not eliminate the risk of TD, emphasizing
the need for pre-travel medical providers to counsel trav-
elers on self-treatment strategies.5
Prevalence of GI symptoms during travel and the impact
of TD on travel-related activities have not been well
described in recent years; current recommendations are
derived from studies from > 20 years ago.1,6–9 The objec-
tive of this study is to describe the types of GI symptoms
occurring during and after travel among more recent
U.S. international travelers. Specifically, we described the
occurrence of TD and non-TD GI symptoms, analyzed
whether travelers took prescribed antidiarrheal medica-
tions (including antimotility and antibiotic agents), the
impact of TD and non-TD GI symptoms on planned activi-
ties, the association of demographic and trip characteris-
tics with TD, and adherence to recommended dietary
prevention measures.
METHODS
The Boston Area Travel Medicine Network (BATMN) is
a research collaboration of travel clinics in the greater
Boston area representing urban-, suburban-, academic-,
and university-affiliated facilities. A convenience sample
of travelers ≥ 18 years of age attending three BATMN
clinics between 2009 and 2011 for pre-travel consulta-
tions completed pre-travel surveys, at least one survey
weekly during travel, and a post-travel survey 2–4 weeks
after return. Travelers were asked to complete a survey at
the end of each week of their trip. Institutional review
board approvals were obtained at all sites and the Cen-
ters for Disease Control and Prevention, and participants
provided written informed consent. Information collected
included demographic and trip characteristics, vaccines
and medications recommended/prescribed before travel,
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medications taken during travel, dietary practices during
travel (consumption of tap water, ice in drinks, unpasteurized
dairy products, and salads), symptoms experienced, and
impact of illness during and after travel. Vaccinations, pre-
scriptions, and travel health advice given during the pre-travel
consultation were recorded by a clinician, and the remainder
of the surveys were completed by the traveler. Data were
entered into a password-protected database (CS Pro, U.S.
Census Bureau, Washington, DC).
TD was defined as diarrhea with or without nausea/
vomiting, abdominal cramps, or fever.10 Non-TD GI symp-
toms described included the following in the absence
of diarrhea: nausea/vomiting, abdominal pain, and con-
stipation. Participants who reported non-GI symptoms
(e.g., joint pain, skin problems, or motion sickness) were
excluded from this analysis. An overview of all health
problems experienced by this cohort has been published
elsewhere.11 We compared those with TD to those who
remained healthy, defined as those who did not report any
symptoms during or after travel. Travel destinations were
grouped by: 1) 2011 United Nations (UN) human develop-
ment index (HDI)12 (if a traveler went to ≥ 1 country, the
lowest ranked country was used) and 2) UN geographic
regions13 (if traveler went to ≥ 1 region, they were catego-
rized as “multiple”).
Demographic and trip characteristics were evaluated by
χ2 test for categorical and Wilcoxon rank-sum test for con-
tinuous variables. Analysis of weekly dietary practices
during travel used logistic generalized estimating equation
models, and analysis of dietary practices during or after
travel used logistic regression models. Variables that were
statistically significant in bivariate analysis were used in
multivariable analysis; destination was included in the final
models because risks for foodborne and waterborne dis-
eases vary by destination.5 Trip duration in days was
included in the multivariable models as a continuous vari-
able. All two-tailed P values < 0.05 were considered statisti-
cally significant. SAS 9.3 (SAS Institute, Cary, NC) was
used for all analyses.
RESULTS
We enrolled 987 travelers; 628 (64%) completed all three
parts (pre-, during, and post-travel) and were included in
the study. Comparison of the 628 to the 359 who did not
complete all three parts (noncompleters) revealed no dif-
ferences, except that completion rates were higher for
white travelers than all other racial/ethnic groups (P <
0.001) and for older travelers (median age 47 years versus
32 years in noncompleters, P < 0.001).11 Of those 628
travelers, 208 (33%) experienced TD, 45 (7%) experienced
non-TD GI symptoms, 147 (23%) experienced non-GI
symptoms, and 228 (36%) did not experience any
symptoms during or after travel. Of the 208 with TD, 140
(67%) reported diarrhea as their only symptom, whereas
33 (16%) also experienced nausea/vomiting, 23 (11%)
abdominal pain, and 27 (13%) fever (Table 1). Of the 45
who reported non-TD GI symptoms, 21 (47%) experienced
nausea/vomiting, 19 (42%) experienced constipation, and
10 (22%) experienced abdominal pain during or after travel
(Table 2). Almost all travelers (99%) received advice about
food and water precautions and diarrhea management dur-
ing pre-travel consultation.
Trip characteristics in those with TD versus those
who remained healthy. Duration of travel was slightly
longer for the 208 with TD than for the 228 travelers who
remained healthy (median, 13 days versus 11 days, P <
0.0001, Table 3). India (total 89 travelers, 48% experienced
TD), South Africa (total 41 travelers, 24% experienced TD),
and Tanzania (total 35 travelers, 43% experienced TD)
were the most common destinations of all travelers. The
relationships of geographic region to TD and level of devel-
opment to TD were not statistically significant (P = 0.06
for the UN region and P = 0.08 for the HDI groupings;
Table 3).
Vaccines and medications prescribed pre-travel and
those taken during travel. Of all 628 travelers, 366 (58%)
were administered hepatitis A vaccine and 445 (71%)
received either oral (164 travelers, 37%) or injectable (281,
63%) typhoid vaccine at the pre-travel consultation. Of
those who experienced TD during or after travel, 126 (61%)
of 208 travelers received hepatitis A vaccine and 151 (73%)
had received typhoid vaccine at the pre-travel consultation.
Those who experienced TD during or after travel were no
more likely to have been vaccinated for hepatitis A (P =
0.43) or typhoid (P = 0.5) at the pre-travel consultation than
those who remained healthy.
Overall, 434 of 628 (69%) travelers were prescribed
ciprofloxacin, 170 (27%) azithromycin, and 377 (60%)
loperamide for TD at the pre-travel consultation. Twenty-
three travelers were not prescribed any antibiotic for TD,
eight of whom reported experiencing diarrhea during or
after travel.
Of 208 travelers who developed TD during or after travel,
200 had been prescribed either ciprofloxacin, azithromycin,
loperamide, or a combination before travel. Of the 200 pre-
scribed, 128 (64%), 71 (36%), and 123 (62%) were pre-
scribed ciprofloxacin, azithromycin, and loperamide before
travel, respectively. One hundred-twenty travelers (58%)
were prescribed loperamide and either ciprofloxacin or
TABLE 1
Gastrointestinal symptoms during and/or after travel among travelers who reported diarrhea (N = 208)
Symptom*
During and after travel During travel only After travel only Total during or after travel
n (% of 208)
Diarrhea 41 (20) 131 (63) 36 (17) 208 (100)
Nausea or vomiting 1 (< 1) 21 (10) 11 (5) 33 (16)
Constipation 4 (2) 19 (9) 7 (3) 30 (14)
Abdominal pain 0 (0) 6 (3) 17 (8) 23 (11)
Fever 0 (0) 21 (10) 6 (3) 27 (13)
*≥ 1 symptom possible for each traveler.
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azithromycin, two travelers were prescribed azithromycin
and ciprofloxacin, and three travelers were prescribed
loperamide alone.
Of the 164 travelers who experienced TD during travel
and were prescribed a specific antibiotic or antidiarrheal
medication at their pre-travel consultation, 75 (46%) of
164 took at least one prescribed medication during
travel. Specifically, 39 (36%) of 108 took prescribed cip-
rofloxacin, 20 (38%) of 55 took prescribed azithromycin,
and 28 (28%) of 99 took prescribed loperamide. Twelve
reported taking loperamide in addition to either cipro-
floxacin or azithromycin.
Changes in planned activities. Of the 172 who experi-
enced TD during travel, 41 (24%) stopped activities, seven
(4%) saw a doctor, and three (2%) were hospitalized
(Figure 1). Of the 41 travelers who experienced TD and
stopped planned activities during travel, 40 had received a
prescription for ciprofloxacin, azithromycin, or loperamide,
or a combination of either ciprofloxacin and loperamide, or
azithromycin and loperamide. Of those who experienced
TD, stopped planned activities during travel, and were pre-
scribed ciprofloxacin, 12 (46%) of 26 self-treated with cip-
rofloxacin. Of those who experienced TD, stopped planned
activities during travel, and were prescribed azithromycin,
five (36%) of 14 self-treated with azithromycin. Of the three
who self-treated with loperamide during travel, two took it
in combination with either ciprofloxacin or azithromycin,
one took it alone. Among the 77 who reported TD after
TABLE 2
Gastrointestinal symptoms during and/or after travel among travelers who did not report diarrhea (N = 45)
Symptom*
During and after travel During travel only After travel only Total during or after travel
n (% of 45)
Nausea or vomiting 2 (4) 12 (27) 7 (16) 21 (47)
Constipation 2 (4) 13 (29) 4 (9) 19 (42)
Abdominal pain 1 (2) 2 (4) 7 (16) 10 (22)
*≥ 1 symptom possible for each traveler.
TABLE 3
Reported TD during or after travel by demographics and trip characteristics (N = 436)
Reported TD during and/or after travel (N = 208) Did not report any symptoms during or after travel (N = 228)
P valuen (row %)
Gender 0.4
Female 125 (49) 128 (51)
Male 83 (45) 100 (55)
Birth country 0.1
Foreign born 31 (39) 48 (61)
U.S. born 176 (49) 180 (51)
Travel reason 0.6
Tourism/vacation 104 (47) 117 (53)
Business 26 (43) 35 (57)
Volunteer/missionary/aid work 20 (42) 28 (58)
Visiting friends and relatives 4 (44) 5 (56)
Educational/research 4 (67) 2 (33)
Other† 48 (54) 41 (46)
Accommodations*
Hotel 139 (49) 143 (51)
Home/local residence 41 (49) 42 (51)
Hostel/budget hotel/guest house 29 (52) 27 (48)
Dormitory 9 (41) 13 (59)
Tent 28 (49) 29 (51)
Ship/yacht/boat 17 (45) 21 (55)
Other‡ 27 (39) 43 (61)
Destination§ 0.06
Low human development 50 (45) 61 (55)
Medium human development 120 (52) 111 (48)
High human development 38 (40) 56 (60)
Destination¶ 0.08
Africa 48 (44) 61 (56)
Asia 74 (56) 58 (44)
Latin America and Caribbean 67 (42) 92 (58)
Multiple 19 (53) 17 (47)
Median (range)
Trip duration∥ (days) 13 (4–65) 11 (3–36) < 0.0001
Age (years) 47 (20–83) 48 (19–81) 0.51
TD = travelers’ diarrhea; UN = United Nations.
*Other category includes those traveling for multiple travel reasons.
†Respondents could have ≥ 1 choice.
‡No text specified.
§Based on UN human development ranking, if traveler went to > 1 country, the lowest ranked country was used.
¶Based on UN regions, if traveler went to > 1 region, they were categorized as “multiple.”
∥Based on dates reported in post-travel survey, P < 0.0001, comparing TD versus no symptoms.
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travel, 17 (22%) stopped activities, 11 (14%) saw a doctor,
and none were hospitalized.
Of the 31 who experienced non-TD GI symptoms during
travel, six (13%) stopped planned activities, three (10%)
saw a doctor, and none were hospitalized. Of the 19 who
reported non-TD GI symptoms after travel, four (21%)
stopped planned activities, three (16%) saw a doctor, and
one went to the emergency room.
Dietary practices during travel. Half or more of those
with TD during or after travel drank tap water, consumed
drinks with ice, ate salads, or consumed unpasteurized dairy
products (Table 4). Consuming any unpasteurized dairy
products was significantly associated with TD (P = 0.02 dur-
ing or after travel, P = 0.01 during travel, Table 4), and those
who experienced TD reported a higher mean number of
days consuming unpasteurized dairy products compared
FIGURE 1. Impact of travelers’ diarrhea during and after travel.
TABLE 4
Bivariate and multivariable analysis of dietary practices and other factors for those who reported TD during or after travel compared with
those who did not report any symptoms
Bivariate
Practice*
Reported TD during or after travel Did not report any symptoms during or after travel
P value† P value‡(N = 208) (N = 228)
n (row %)
Drank tap water 32 (50) 32 (50) 0.69 0.84
Had ice in drinks 107 (48) 114 (52) 0.8 0.87
Consumed unpasteurized dairy products 59 (58) 43 (42) 0.02 0.01
Ate salads 119 (50) 120 (50) 0.36 0.58
Multivariable§
During or after travel During travel only
(logistic) (GEE)
Variable OR (95% CI) P value OR (95% CI) P value
Consumed unpasteurized dairy products 1.69 (1.06–2.70) 0.03 1.00 (0.99–1.00) 0.08
Trip duration¶ 1.06 (1.02–1.09) < 0.01 1.06 (1.03–1.10) < 0.01
Destination 0.43 0.32
Asia Ref Ref
Africa 0.65 (0.38–1.11) 0.68 (0.39–1.20)
Latin America and Caribbean 0.84 (0.50–1.40) 0.81 (0.47–1.40)
Multiple 1.01 (0.47–2.16) 1.31 (0.61–2.82)
BATMN = Boston Area Travel Medicine Network; CI = confidence interval; GEE = generalized estimating equation; GI = gastrointestinal; OR = odds ratio; TD = travelers’ diarrhea.
*Totals: drank tap water = 64 (15%), had ice in drinks = 221 (51%), consumed unpasteurized dairy products = 102 (24%), and ate salads = 239 (55%).
† If yes during any week during travel, then yes for the total trip (χ2). Outcome is anybody who reported GI illness during or after travel.
‡Yes/no response for each week during travel (GEE model with autoregressive correlation matrix). Outcome is anybody who reported GI illness during travel only.
§All models control for BATMN site.
¶Continuous variable (in days).
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with those who remained healthy (2.3 days [range 0–21]
versus 1.2 days [range 0–24], P = 0.008). In multivariable
analysis, trip duration (days, continuous) remained associ-
ated with TD (odds ratio [OR] = 1.06, 95% confidence inter-
val [CI] = 1.02–1.09, for TD during and/or after travel, OR =
1.06, 95% CI = 1.03–1.10 for TD during travel only, Table 4).
DISCUSSION
Travelers experienced both TD and non-TD GI symptoms
during and after travel. Together, TD and non-TD GI symp-
toms affected 40% of travelers resulting in interruption of
planned trip activities and healthcare visits for some. Despite
receiving advice about food and water precautions before
travel, travelers still engaged in risky dietary practices and
experienced TD. Of those who experienced TD, 83% reported
diarrhea during travel, and one-third experienced diarrhea in
addition to other GI symptoms. TD continues to remain the
leading illness experienced during and after travel.1,14,15
Trip duration was found to be statistically associated with
TD in our study, with those experiencing TD traveling slightly
longer than those who did not experience TD. Other studies
have shown longer duration of travel to be associated with an
increase in certain GI symptoms (e.g., diarrhea) in travelers.7,14
Although greater quantitative detail about disruption in activi-
ties during and after travel could not be provided through our
study, TD may interrupt plans for approximately 20–25% of
travelers, including missing work, school, or other planned
activities. Clinicians should take special note of those travel-
ing for longer periods of time and emphasize strategies to
avoid or treat TD. Although the association of TD with geo-
graphic region and level of development were not statistically
significant, larger proportions of travelers to multiple regions
and travelers to Asia or Africa experienced TD compared with
travelers to Latin America and the Caribbean. Similarly, a
larger proportion of travelers to medium and low HDI groups
experienced TD than those in the high HDI group. Previous
studies have generally demonstrated a higher risk for TD in
travelers to Africa and Asia10,16,17 or among travelers visiting
medium and low HDI countries.14,18,19
When travelers experienced TD during their trip, 46% of
those prescribed antidiarrheal or antibiotic agents before
travel took them to treat their symptoms. The proportion of ill
travelers who took some form of self-treatment of TD was
lower than reported in other cohort studies of American trav-
elers going to developing countries who were prescribed anti-
diarrheal and antibiotic agents before travel.7,20 Because TD
resulted in interruption of activities and healthcare visits in
this study, providing antimicrobials for self-treatment of TD
remains an acceptable practice, but advising travelers about
judicious use of these antimicrobials, such as reserving their
use for more severe illness, would be appropriate.
Pre-travel medical advice for the traveler consists of
destination-dependent food and water precautions, as
well as counseling about, and prescription for, self-
treatment if illness occurs.21 Steffen and others found that
there was no difference between travelers with or without
diarrhea and their relative consumption of high-risk foods
or drink16; travelers who followed at least three food/water
precautions actually had a higher incidence of TD than
those who did not.8 Adherence to recommended food and
water precautions has not demonstrated clear efficacy in
preventing illness, and it has been suggested that risk of
TD is related more to the sanitation level at the destination
rather than the traveler’s ability to adhere to dietary mea-
sures.22 Consequently, pre-travel advice on self-treatment
strategies is recommended, as avoiding illness may, in
many cases, be beyond the traveler’s control.5 Although
our study did not collect outcome data for those who self-
treat their illness during travel, studies have found TD treat-
ment during travel to be effective.7,23 Advice about food
and water precautions continues to be prudent in a global
environment where safe water cannot be assured; however,
advice from healthcare providers about self-treatment strat-
egies should be detailed enough to allow the traveler to
make better decisions regarding when to use prescribed
and recommended medications.
Several limitations exist for our study. Patients seen at
the three BATMN clinics may not be representative of inter-
national travelers in general. Symptoms were self-reported;
we were unable to confirm etiology of symptoms during or
after travel. We cannot confirm that the travel diaries were
completed during travel and not at a later date since partici-
pants were allowed up to 4 weeks after their trip to turn in
the travel diaries and post-travel surveys, therefore recall
bias may be present. GI symptoms with onset reported
after travel may not necessarily be travel-related due to the
timing of the post-travel survey. We were unable to collect
data to determine whether travelers were recommended for
hepatitis A or typhoid vaccine, only if they had received
vaccine at the pre-travel visit. Despite receiving a pre-
scription for an antibiotic or loperamide and experiencing
diarrhea during travel, we were unable to determine the rea-
sons for not self-treating with prescribed medication. Lastly,
ORs overstate the relative risk when the outcome is com-
mon; therefore, the adjusted odds ratios may suggest
biased results.24
In summary, travelers continue to experience GI symp-
toms during and after travel which can interrupt their travel
activities and plans after returning home. Non-TD GI symp-
toms occur in travelers, and clinicians may consider strate-
gies in the pre-travel consultation to help patients mitigate
the effects of both TD and non-TD GI symptoms during
and after travel. Pre-travel counseling about safe food and
water consumption practices does not necessarily prevent
illness. Healthcare providers should consider providing
medications to treat TD for those traveling for longer
periods; clearly communicating the utility of, and specific
indications for, self-treatment will help to minimize the dis-
ruption these illnesses may cause.
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